InterPAD - DETAILS

BALSALAZIDE, 80573-04-2, Balsalazido, Balsalazida, Balsalazidum, Balsalazidum [Latin], Balsalazida [Spanish], Balsalazido [Spanish], Colazal, (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid, Colazide, (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid, Balsalazide (INN), CHEBI:267413, P80AL8J7ZP, DTXSID7040653, (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid, 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid, 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid, Giazo, 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid, NCGC00164634-01, BALSALAZIDE [INN], Balsalazide [INN:BAN], DTXCID5020653, 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid, Balsalazide-d3DisodiumSalt, (E)-5-[[[-4-(2-Carboxyethyl)aminocarbonyl]phenyl]azo]-2-hydroxybenzoic acid, 5-((4-((2-carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid, CAS-80573-04-2, UNII-P80AL8J7ZP, 5-({4-[(2-Carboxyethyl)carbamoyl]phenyl}diazenyl)-2-hydroxybenzoic acid, BALSALAZIDE [MI], BALSALAZIDE [VANDF], BALSALAZIDE [WHO-DD], MLS001424257, BIDD:GT0772, SCHEMBL118300, SCHEMBL138311, SCHEMBL142548, CHEMBL1201346, CHEMBL1208641, SCHEMBL15841310, CHEBI:94605, GTPL11569, DTXSID50861027, IPOKCKJONYRRHP-UHFFFAOYSA-N, HMS2052K19, HMS2233C19, HMS3369E09, HMS3394K19, HY-B0667, Tox21_112252, BDBM50565694, MFCD00868204, s4842, 5-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl)-2-hydroxybenzoic acid, AKOS015892568, Tox21_112252_1, AC-8500, CCG-101140, DB01014, KS-5215, NC00390, Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-, NCGC00164634-02, 399030-81-0, AS-17568, SMR000469221, FT-0602905, NS00038077, D07488, EN300-119538, F85019, AB01209737-01, A839951, Q347337, Q-200671, Q27166431, 5-[4-(2-Carboxyethylcarbamoyl)phenylazo]salicylic acid, Bacitracin zinc, Antibiotic for Culture Media Use Only, Z2588038982, (E)-5-((4-(2-carboxyethylcarbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid, BENZOIC ACID, 5-((4-(((2-CARBOXYETHYL)AMINO)CARBONYL)PHENYL)AZO)-2-HYDROXY-, Benzoic acid, 5-[(1E)-2-[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]diazenyl]-2-hydroxy-, (3E)-3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid, 3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazono]-6-oxo-cyclohexa-1,4-diene-1-carboxylic acid, 3-[[4-[(2-carboxyethylamino)-oxomethyl]phenyl]hydrazinylidene]-6-oxo-1-cyclohexa-1,4-dienecarboxylic acid

Name	Balsalazide
PubChem CID	54585
Molecular Weight	357.32g/mol
Synonyms	BALSALAZIDE, 80573-04-2, Balsalazido, Balsalazida, Balsalazidum, Balsalazidum [Latin], Balsalazida [Spanish], Balsalazido [Spanish], Colazal, (E)-5-((4-((2-Carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid, Colazide, (E)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acid, Balsalazide (INN), CHEBI:267413, P80AL8J7ZP, DTXSID7040653, (E)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acid, 5-[4-(2-carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acid, 5-[(E)-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazenyl]-2-hydroxybenzoic acid, Giazo, 3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid, NCGC00164634-01, BALSALAZIDE [INN], Balsalazide [INN:BAN], DTXCID5020653, 5-[[4-(2-carboxyethylcarbamoyl)phenyl]diazenyl]-2-hydroxybenzoic acid, Balsalazide-d3DisodiumSalt, (E)-5-[[[-4-(2-Carboxyethyl)aminocarbonyl]phenyl]azo]-2-hydroxybenzoic acid, 5-((4-((2-carboxyethyl)carbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid, CAS-80573-04-2, UNII-P80AL8J7ZP, 5-({4-[(2-Carboxyethyl)carbamoyl]phenyl}diazenyl)-2-hydroxybenzoic acid, BALSALAZIDE [MI], BALSALAZIDE [VANDF], BALSALAZIDE [WHO-DD], MLS001424257, BIDD:GT0772, SCHEMBL118300, SCHEMBL138311, SCHEMBL142548, CHEMBL1201346, CHEMBL1208641, SCHEMBL15841310, CHEBI:94605, GTPL11569, DTXSID50861027, IPOKCKJONYRRHP-UHFFFAOYSA-N, HMS2052K19, HMS2233C19, HMS3369E09, HMS3394K19, HY-B0667, Tox21_112252, BDBM50565694, MFCD00868204, s4842, 5-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl)-2-hydroxybenzoic acid, AKOS015892568, Tox21_112252_1, AC-8500, CCG-101140, DB01014, KS-5215, NC00390, Benzoic acid, 5-((4-(((2-carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxy-, (E)-, NCGC00164634-02, 399030-81-0, AS-17568, SMR000469221, FT-0602905, NS00038077, D07488, EN300-119538, F85019, AB01209737-01, A839951, Q347337, Q-200671, Q27166431, 5-[4-(2-Carboxyethylcarbamoyl)phenylazo]salicylic acid, Bacitracin zinc, Antibiotic for Culture Media Use Only, Z2588038982, (E)-5-((4-(2-carboxyethylcarbamoyl)phenyl)diazenyl)-2-hydroxybenzoic acid, BENZOIC ACID, 5-((4-(((2-CARBOXYETHYL)AMINO)CARBONYL)PHENYL)AZO)-2-HYDROXY-, Benzoic acid, 5-[(1E)-2-[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]diazenyl]-2-hydroxy-, (3E)-3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acid, 3-[[4-(2-carboxyethylcarbamoyl)phenyl]hydrazono]-6-oxo-cyclohexa-1,4-diene-1-carboxylic acid, 3-[[4-[(2-carboxyethylamino)-oxomethyl]phenyl]hydrazinylidene]-6-oxo-1-cyclohexa-1,4-dienecarboxylic acid
Drug Type	Small molecule
Formula	C₁₇H₁₅N₃O₆
SMILES	C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
InChI	1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)
InChIKey	IPOKCKJONYRRHP-UHFFFAOYSA-N
ChEMBL ID	CHEMBL1208641
ChEBI ID	CHEBI:267413
TTD ID	D0A6KR
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Parthenolide, Balsalazide
Partner Name	Parthenolide
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	CASP3	hsa836
	Down-regulation	Expression	CASP8	hsa841
	Down-regulation	Expression	CASP9	hsa842
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CFLAR	hsa8837
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Activity	NFKB1	hsa4790
	Down-regulation	Phosphorylation	NFKBIA	hsa4792
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Expression	PTGS2	hsa5743
	Up-regulation	Expression	TP53	hsa7157
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
Result	These results demonstrate that parthenolide potentiates the efficacy of balsalazide through synergistic inhibition of NF-κB activation and the combination of dual agents prevents colon carcinogenesis from chronic inflammation.